Viridian Therapeutics, Inc.\DE (VRDN) Research & Development (2013 - 2026)
Viridian Therapeutics, Inc.\DE's Research & Development was $71.58 million in Q2 2026, down 17.4% from $86.63 million a year earlier and down 7.8% from the prior quarter.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Research & Development (2013 - 2026) Analysis & Trends
On a trailing twelve-month basis, Viridian Therapeutics, Inc.\DE's Research & Development was $324.68 million through Jun 30, 2026, up 6.6% year-over-year; for FY2025, it was $338.93 million, up 42.3% from FY2024.
- Research & Development has now increased for five consecutive years, with a five-year compound annual growth rate of 64.3% (FY2020 to FY2025).
- In earlier years, Research & Development was $238.25 million in FY2024 (+49.1%), $159.77 million in FY2023 (+58.3%), $100.89 million in FY2022 (+77.4%) and $56.89 million in FY2021 (+101.0%).
- The Q2 2026 figure marks the lowest quarterly Research & Development since Q3 2024.
- Compared with a year earlier, Research & Development was higher in seven of the last eight quarters, with growth averaging 48.6%.
- The best year-over-year quarter for Research & Development over five years was Q1 2023 (growth of 185.9%); the worst was Q1 2024 (a decline of 19.3%).
- Per Business Quant data, VRDN's Research & Development in the three quarters before Q2 2026 was $77.63 million (Q1 2026), $89.21 million (Q4 2025) and $86.26 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | -691.75 Mn | - | 71.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 71.58 Mn |
| Mar 31, 2026 | 77.63 Mn |
| Dec 31, 2025 | 89.21 Mn |
| Sep 30, 2025 | 86.26 Mn |
| Jun 30, 2025 | 86.63 Mn |
| Mar 31, 2025 | 76.84 Mn |
| Dec 31, 2024 | 71.96 Mn |
| Sep 30, 2024 | 69.16 Mn |
| Jun 30, 2024 | 56.19 Mn |
| Mar 31, 2024 | 40.94 Mn |
| Dec 31, 2023 | 38.56 Mn |
| Sep 30, 2023 | 30.39 Mn |
| Jun 30, 2023 | 40.08 Mn |
| Mar 31, 2023 | 50.74 Mn |
| Dec 31, 2022 | 39.32 Mn |
| Sep 30, 2022 | 22.12 Mn |
| Jun 30, 2022 | 21.71 Mn |
| Mar 31, 2022 | 17.75 Mn |
| Dec 31, 2021 | 22.39 Mn |
| Sep 30, 2021 | 8.12 Mn |
API Access
Viridian Therapeutics, Inc.\DE Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=VRDN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "VRDN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=VRDN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();